AXSOME THERAPEUTICS, INC. Finance Lease, Principal Payments
AXSOME THERAPEUTICS, INC. (AXSM) reported Finance Lease, Principal Payments of $1.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2026-06-30 was $1.21M, a 133.59% increase year-over-year.
- AXSOME THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2026-03-31 was $672.00K, a 67.58% increase year-over-year.
- AXSOME THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2025-12-31 was $541.00K, a 63.94% increase year-over-year.
- AXSOME THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2025-09-30 was $664.00K, a 113.50% increase year-over-year.
- AXSOME THERAPEUTICS, INC. finance lease, principal payments for fiscal 2025 was $2.12M, a 114.55% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. finance lease, principal payments for fiscal 2024 was $990.00K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.88M 10-Q · filed 2026-08-10 | $2.42M derived: sum of 3 quarters · filed 2026-08-10 | $3.09M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $672.00K 10-Q · filed 2026-05-04 | $1.21M derived: sum of 2 quarters · filed 2026-05-04 | $1.88M derived: sum of 3 quarters · filed 2026-05-04 | $2.40M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $541.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.21M derived: sum of 2 quarters · filed 2026-02-23 | $1.72M derived: sum of 3 quarters · filed 2026-08-10 | $2.12M 10-K · filed 2026-02-23 |
| 2025-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.18M derived: sum of 2 quarters · filed 2026-08-10 | $1.58M 10-Q · filed 2025-11-03 | $1.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $518.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $919.00K 10-Q · filed 2026-08-10 | $1.25M derived: sum of 3 quarters · filed 2026-08-10 | $1.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $401.00K 10-Q · filed 2026-05-04 | $731.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.04M derived: sum of 3 quarters · filed 2026-05-04 | $1.23M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $330.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $641.00K derived: sum of 2 quarters · filed 2026-02-23 | $827.00K derived: sum of 3 quarters · filed 2026-02-23 | $990.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $311.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $497.00K derived: sum of 2 quarters · filed 2025-11-03 | $660.00K 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $349.00K 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $163.00K 10-Q · filed 2025-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |